-
2020 Medical People Eat Melon Summary Report
Time of Update: 2021-01-21
At the beginning of 2020, a sudden outbreak made the breath of the New Year chill. can say that at the beginning of the year all the focus is on the situation of the epidemic. as the outbreak was gr
-
Double-sided angel - ketamine's tortuous research and development path
Time of Update: 2021-01-07
In 2006, a NIH clinical study of patients with refractic depression in the United States had similar results, with a single intravenous sub-anaesthetic dose of ketamine, which quickly produced significant antidepressant effects and sustained a week of treatment.
-
Turn a profit for the first time! Ali Health shows what kind of Internet medical development path
Time of Update: 2021-01-07
2021 fiscal year interim results announcement data show that Ali Health Pharmaceutical's own business revenue of 6.04 billion yuan, up 75.7% YoY, pharmaceutical e-commerce platform service revenue of 930 million yuan, up 71.4% YoY.
-
"Pharmaceutical Headlines" 500 list announced that "medicine again record high these white horses but...
Time of Update: 2021-01-07
(2020/11/30) Novarma Adakveo rejected in the UK to prevent relapse sickle cell crisis; health insurance: how to fill the gap between product supply and demand for security; 200 million elderly people 40 million degenerative people This is Chinese's most needed and life-time insurance ...
-
Lisheng pharmaceutical pyrethride tablets are evaluated by generic drug consistency
Time of Update: 2021-01-07
Edema-related diseases include congestive heart failure, cirrhosis of the liver, kidney disease (acute and chronic renal failure due to nephritis, kidney disease and various causes), especially when the use of other diuretics is not effective, the application of this type of drug may still be effective.
-
Time of Update: 2021-01-07
2. Relying on Mimi esters its side effects are greater, but due to the cardiovascular, respiratory circulation impact is small, can be used as a substitute for propofol, the market growth is also relatively rapid, the current production enterprises include the local Enhua Pharmaceuticals, Jiuxu Pharmaceuticals, Hengrui Pharmaceuticals, foreign companies originally researched in Germany Belang, Jiangsu Enhua occupies more than 70% of the market share, Belang only about 20%.
-
Hengrui Pharmaceutical Toluene Sulphate Remazene declared a third adaptive disorder
Time of Update: 2021-01-07
On December 2, according to the CDE official website Hengrui Pharmaceutical injection with toluene sulfonate remazene third new adaptive disease listing application was accepted, according to the drug conducted in the domestic clinical trials, the author speculated that the declared new adaptive is general anaesthetic.
-
"Pharmaceutical Speed Reading Society" Thyda / Lilly double anti-approved clinical medical insurance bureau response to chinese medicine collection ...
Time of Update: 2021-01-07
December 2, 2020 / Medicines At a Glance: Pfizer/BioNTech's new crown vaccine is the first in the UK to be licensed for emergency use; AstraZenece's $350 million sale of the best-selling cholesterol drug Crestor-related rights; Cinda/Lilly Double Resistance Approved Clinically; and the National Health Insurance Administration responds to the issue of chinese medicine collection...
-
Enhua preempted the first review! 2 billion
Time of Update: 2021-01-06
On December 11, NMPA's official website released the latest approved product information, Enhua Pharmaceuticals' 3 types of imitation market application for sci-fi injections was approved and evaluated, earlier only IDT approved imports and Yichang People's Fu Pharmaceuticals obtained domestic approval, the product for the annual sales of more than 2 billion pounds of heavy anaesthetic injections.
-
Research and development daily Roche multiple sclerosis drug Ocrevus has been approved by the FDA...
Time of Update: 2021-01-06
2020.12.15 Research and development NEWS: Roche multiple sclerosis drug Ocrevus was approved by the FDA again; platinum pharmaceutical jointly announced the approval of AbbVie's new coronary antibody Phase 1 clinical trial started; Novartis JAK inhibitor Jakavi treatment hospitalized COVID-19 patients Phase III clinical failure; Astella ADC therapy approved clinical ...
-
Young doctors under the impact of the price slash on supplies
Time of Update: 2021-01-06
Not a good year: busy, fine and patient complaints endocrinologist Liu Yu, when it comes to the past few months when the state collected drugs into the hospital, the hospital in order to complete the volume of procurement indicators, the computer system is always suddenly unable to open the original drug, still some anger.
-
Another subsidiary of The Micro-Invascope Medical Spin-Off has recently been listed three times
Time of Update: 2021-01-06
Finishing: Chocolate Micro-Invasive Medical continued to split recently, Micro-Invasive Medical announced that it is considering a possible spin-off of the company's non-whowicial subsidiary Micro-In
-
Once again catch-up Fu Enhua Pharmaceuticals Mida Zolun injection was approved through a consistent evaluation
Time of Update: 2021-01-05
according to meters of intranet data, in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal psychostational injection varieties TOP20, Midazolam ranked second, sales in 2019 more than 600 million yuan, the first half of 2020 leading enterprise Enhua market share remained at about 80%, the market share of Human Fu also reached 17.80%.
-
In 2020, China's State Drug Administration approved the listing of 12 innovative drugs
Time of Update: 2021-01-05
2, Howson Pharmaceuticals: Amethystini Target/Mechanism of Action: 3rd Generation EGFR-TKI March 31, NMPA announces conditional approval of the listing of Haussen Pharmaceuticals' Class 1 innovative drug methyndinib tablets for use in the past The disease progression occurs during or after treatment of the skin growth factor subject (EGFR) tyrosine kinase inhibitor (TKI) and is confirmed to be positive for EGFR T790M mutation in adult patients with local late stage or metastasis non-small cell lung cancer (NSCLC).
-
Ted Pharmaceuticals' muscular pine drug benzodiaxane aquco ammonium injection has been officially approved for the market
Time of Update: 2021-01-05
(Product Effect Map) Benzene Shun Acura ammonium is a medium-effect, non-depolarized skeletal muscle relaxant with a pyrethroid structure that can be used as an all-hemp-assisted medication or as a sedative in the intensive care unit (ICU).
-
Nanjing Jianyou, Beijing Ted "Benzene Shun Aquku ammonium injection" will soon be approved for the market
Time of Update: 2021-01-05
December 17, Nanjing Jianyou, Beijing Ted according to the 4 categories of registered declaration of benzene sulfon Shun Aquku ammonium injection is in the "in the approval" stage, is expected to be approved by the State Drug Administration in the near future, the first to pass the consistent evaluation of the two enterprises.
-
13 varieties were evaluated with consistent evaluation of sodium cephalosporine
Time of Update: 2021-01-05
Content source: Pharmaceutical Rubik's Cube Info December 25, the official website of the State Drug Administration shows 13 generic drugs through the consistent evaluation, among them, Zhejiang Huideson and Shandong Runze injection of cephalosporine sodium, Beijing Ted and Nanjing Jianyou's benzene shun aquku ammonium injection are the first simultaneous evaluation varieties.
-
2 domestic 1 class of new drugs approved for listing! Novarthren Jianhua's first innovative drug is about to be approved
Time of Update: 2021-01-05
This week look at point 1. International drug dynamics 2. Two domestic 1 class 1 new drugs were approved for market! 3. No cheng Jianhua's first innovative drug Abtini tablets will soon be approved 4
-
BMJ: Playing soothing music during surgery can reduce postoperative pain
Time of Update: 2020-12-24
addition, playing music to patients through headphones during general anaesthetic surgery can reduce postoperative pain and opioid use as a safe, viable, and non-drug pain relief method.
-
BMJ: Comparison of the clinical outcome of neuroaxial anesthesia with general anesthesia during vascular reconstruction surgery in the lower extremities of adults
Time of Update: 2020-12-14
, the use of neural axis anesthesia in vascular recirculation surgery in the lower extremities reduced mortality and hospital stay by 30 days compared to general anaesthetic.
